| pubmed-article:10650181 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C0006864 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C0205345 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C2709199 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C1752435 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C1705241 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C0439097 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:10650181 | lifeskim:mentions | umls-concept:C1547348 | lld:lifeskim |
| pubmed-article:10650181 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10650181 | pubmed:dateCreated | 2000-3-28 | lld:pubmed |
| pubmed-article:10650181 | pubmed:abstractText | We demonstrated that in vivo administration of Delta(9)-tetrahydrocannabinol in mice (15 mg/kg s.c.) significantly inhibited natural killer cell (NK) cytolytic activity without affecting Concanavalin A (ConA)-induced splenocyte proliferation. Moreover, we investigated the effect of in vivo pretreatment with cannabinoid receptor antagonists, namely, the selective cannabinoid CB(1) receptor antagonist SR 141716 [N-piperidin-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide] and the selective cannabinoid CB(2) receptor antagonist SR 144528 ¿N-[(1S)-endo-1,3, 3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazo le- 3-carboxamide¿, on Delta(9)-tetrahydrocannabinol-induced inhibition of NK cytolytic activity. Both antagonists partially reversed the Delta(9)-tetrahydrocannabinol inhibition of NK cytolytic activity, although the cannabinoid CB(1) receptor antagonist was more effective than the cannabinoid CB(2) receptor antagonist. The parallel measurement of interferon gamma and interleukin 2 levels revealed that Delta(9)-tetrahydrocannabinol significantly reduced (about 70%) the former cytokine without affecting the latter. Cannabinoid CB(1) and CB(2) receptor antagonists completely reversed the interferon gamma reduction induced by Delta(9)-tetrahydrocannabinol. Our results indicate that both types of cannabinoid receptors are involved in the complex network mediating NK cytolytic activity. | lld:pubmed |
| pubmed-article:10650181 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10650181 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10650181 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10650181 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:10650181 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:10650181 | pubmed:author | pubmed-author:ParolaroDD | lld:pubmed |
| pubmed-article:10650181 | pubmed:author | pubmed-author:SacerdotePP | lld:pubmed |
| pubmed-article:10650181 | pubmed:author | pubmed-author:MassaHH | lld:pubmed |
| pubmed-article:10650181 | pubmed:author | pubmed-author:FuzioDD | lld:pubmed |
| pubmed-article:10650181 | pubmed:author | pubmed-author:ViganòDD | lld:pubmed |
| pubmed-article:10650181 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10650181 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:10650181 | pubmed:volume | 387 | lld:pubmed |
| pubmed-article:10650181 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10650181 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10650181 | pubmed:pagination | 343-7 | lld:pubmed |
| pubmed-article:10650181 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:meshHeading | pubmed-meshheading:10650181... | lld:pubmed |
| pubmed-article:10650181 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10650181 | pubmed:articleTitle | Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. | lld:pubmed |
| pubmed-article:10650181 | pubmed:affiliation | Department of Pharmacology, Chemotherapy and Toxicology, University of Milan, Via Vanvitelli 32/A, 20129, Milan, Italy. | lld:pubmed |
| pubmed-article:10650181 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10650181 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10650181 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10650181 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10650181 | lld:pubmed |
